贝伐珠单抗联合热灌注化疗方案治疗晚期卵巢癌的近远期效果及其对VEGF、HDGF和MIF表达水平的影响  

Short-term and long-term effects of Bevacizumab combined with hyperthermic perfusion chemotherapy in the treatment of advanced ovarian cancer and its influence on expression of VEGF,HDGF and MIF

作　　者：韦惠章 潘嘉问 薛协持 麦哲林 

机构地区：[1]广东省鹤山市人民医院内二科,广东鹤山529700

出　　处：《中国医药导报》2016年第8期25-28,共4页China Medical Herald

基　　金：广东省自然科学基金项目(S2013020012660)

摘　　要：目的探讨贝伐珠单抗联合热灌注化疗方案治疗晚期卵巢癌的近远期效果及其对血管内皮生长因子（VEGF）、肝细胞瘤衍生生长因子（HDGF）和巨噬细胞移动抑制因子（MIF）表达水平的影响。方法选取2008年6月～2013年9月鹤山市人民医院诊治的74例卵巢癌患者为研究对象，依据肿瘤细胞减灭术后治疗方案的不同将患者分为单独热灌注化疗组（单独组）和贝伐珠单抗＋热灌注化疗组（联合组），每组各37例。比较两组患者近远期临床治疗效果及VEGF、HDGF和MIF表达水平。结果单独组和联合组的治疗有效率分别为64．86％和89．19％，联合组明显高于单独组，差异有统计学意义（P〈0．05）；两组患者疾病控制率和不良反应发生率比较差异均无统计学意义（P〉0．05）。随访结果显示，尽管两组患者1年生存率比较差异无统计学意义（P〉0．05），但联合组患者2年生存率（48．65％）明显高于单独组（18．92％）（P〈0．01）；联合组患者平均生存时间明显长于单独组，差异有高度统计学意义（P〈0．01），局部复发率与转移率显著低于单独组，差异有统计学意义（P〈0．05）。单独组患者VEGF、HDGF和MIF的mRNA表达和蛋白含量均显著高于联合组，差异均有统计学意义（P〈0．05或P〈0．01）。结论贝伐珠单抗联合热灌注化疗方案治疗晚期卵巢的近远期临床效果优于单独灌注化疗，且可以显著抑制肿瘤侵袭关键因子VEGF、HDGH和MIF的表达。Objective To investigate the short-term and long-term effects of Bevacizumab combined with hyperthermic perfusion chemotherapy in the treatment of advanced ovarian cancer and its influence on vascular endothelial growth factor （VEGF）, hepatoma derived growth factor （HDGF） and macrophage migration inhibitory factor （MIF）. Methods From June 2008 to September 2013, 74 cases of advanced ovarian cancer in the People＇s Hospital of Heshan City were se- lected as the research objects, who were divided into single hyperthermic perfusion chemotherapy （single group） and Bevacizumab plus hyperthermic perfusion chemotherapy group （combined group） according to different therapeutic sched- ule after cytoreductive surgery, each group had 37 cases. The short-term and long-term effects, the levels of VEGF, HDGF and MIF were compared between two groups. Results The treatment efficiency rate of single and combined groups were 64.86% and 89.19%, and the combined group was significantly higher than that of single group, the differ- ence was statistically significant （P 〈 0.05）. There were no significant difference in the disease control rate and adverse reaction incidence rate between two groups （P 〉 0.05）. Follow-up results showed that although no significant difference was observed in the 1 year survival rate of two groups （P 〉 0.05）, but the 2 years survival rate of the combined group （48.65%） was significantly higher than that of the single group （18.92%）, the difference was statistically significant （P 〈0.01）; in addition, the average survival time of patients in the combined group was significantly longer than that of single group, the difference was statistically significant（P 〈 0.01）, and the local recurrence rate and metastasis rate was significantly lower than that of the single group, the differences were statistically significant （P 〈 0.05）. The protein content and mRNA expression of VEGF, HDGF and MIF in the single group were significantly higher than those

关 键 词：贝伐珠单抗 热灌注化疗 卵巢癌 血管内皮生长因子 肝细胞瘤衍生生长因子 巨噬细胞移动抑制因子 

分 类 号：R737.31[医药卫生—肿瘤]